Skip to main content
. 2016 Sep-Oct;48(5):503–508. doi: 10.4103/0253-7613.190721

Table 3.

Biochemical safety parameters at baseline and at 12 weeks in rosuvastatin and placebo group

graphic file with name IJPharm-48-503-g003.jpg